The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2012 Jun 8

PMID 22673731

Citations 174

Authors

David A Martin

Jennifer E Towne

Gregory Kricorian

Paul Klekotka

Johann E Gudjonsson

James G Krueger

Chris B Russell

Affiliations

Soon will be listed here.

Abstract

Although the histological changes seen in psoriasis have long been well characterized, the underlying cellular and molecular mechanisms have only begun to be elucidated over the past 20 years. Proinflammatory factors such as tumor necrosis factor (TNF)-α have a central role in psoriasis pathogenesis, and many T-helper 1 (Th1) cytokines and messenger RNAs are elevated in psoriatic lesions. IL-17A, IL-17F, and other Th17 cell-derived cytokines have been shown in murine models to induce features that mimic human psoriasis. This review focuses on the emerging biology of the IL-17 cytokine family in psoriasis, and on the molecular and genetic information gained from animal models and human clinical studies that confirm IL-17 as a crucial proinflammatory cytokine in psoriasis. Expression of IL-17A, IL-17C, and IL-17F is strikingly increased in psoriatic lesions, and successful therapy is associated with restoration of the expression of a wide range of genes (including effector molecules downstream of IL-17 such as cytokines, chemokines, and antimicrobial peptides) to near-normal levels. Therapeutic agents in development that target IL-17 are discussed, and an emerging model of the key role of IL-17 in the pathogenesis of psoriasis is presented.

Citing Articles

Liposomes and Their Therapeutic Applications in Enhancing Psoriasis and Breast Cancer Treatments.

Elkordy A, Hill D, Attia M, Chaw C Nanomaterials (Basel). 2024; 14(21).

PMID: 39513840 PMC: 11547384. DOI: 10.3390/nano14211760.

Sphingosine 1-phosphate receptor 2 in keratinocytes plays a key role in reducing inflammation in psoriasis.

Masuda-Kuroki K, Alimohammadi S, Lowry S, Di Nardo A Front Immunol. 2024; 15:1469829.

PMID: 39391307 PMC: 11464331. DOI: 10.3389/fimmu.2024.1469829.

The DNA sensor AIM2 mediates psoriasiform inflammation by inducing type 3 immunity.

Martins T, Silva de Melo B, Toller-Kawahisa J, Victor Lucena da Silva G, Anibal Silva C, Paiva I JCI Insight. 2024; 9(21).

PMID: 39352743 PMC: 11601563. DOI: 10.1172/jci.insight.171894.

p38α deficiency ameliorates psoriasis development by downregulating STAT3-mediated keratinocyte proliferation and cytokine production.

Zheng T, Deng J, Wen J, Xiao S, Huang H, Shang J Commun Biol. 2024; 7(1):999.

PMID: 39147860 PMC: 11327308. DOI: 10.1038/s42003-024-06700-w.

Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review.

Leong H, Wang W, Peng F Postepy Dermatol Alergol. 2024; 41(3):262-269.

PMID: 39027700 PMC: 11253319. DOI: 10.5114/ada.2024.141128.

References

Yang L, Anderson D, Baecher-Allan C, Hastings W, Bettelli E, Oukka M . IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008; 454(7202):350-2. PMC: 2760130. DOI: 10.1038/nature07021. View

Cargill M, Schrodi S, Chang M, Garcia V, Brandon R, Callis K . A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007; 80(2):273-90. PMC: 1785338. DOI: 10.1086/511051. View

Honorati M, Meliconi R, Pulsatelli L, Cane S, Frizziero L, Facchini A . High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. Rheumatology (Oxford). 2001; 40(5):522-7. DOI: 10.1093/rheumatology/40.5.522. View

Papp K, Leonardi C, Menter A, Ortonne J, Krueger J, Kricorian G . Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366(13):1181-9. DOI: 10.1056/NEJMoa1109017. View

Ma H, Liang S, Li J, Napierata L, Brown T, Benoit S . IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008; 118(2):597-607. PMC: 2200300. DOI: 10.1172/JCI33263. View

Zaba L, Suarez-Farinas M, Fuentes-Duculan J, Nograles K, Guttman-Yassky E, Cardinale I . Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009; 124(5):1022-10.e1-395. PMC: 2852188. DOI: 10.1016/j.jaci.2009.08.046. View

Wright J, Bennett F, Li B, Brooks J, Luxenberg D, Whitters M . The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008; 181(4):2799-805. DOI: 10.4049/jimmunol.181.4.2799. View

Gottlieb S, Gilleaudeau P, Johnson R, Estes L, Woodworth T, Gottlieb A . Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995; 1(5):442-7. DOI: 10.1038/nm0595-442. View

Gaffen S . Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011; 23(5):613-9. PMC: 3190066. DOI: 10.1016/j.coi.2011.07.006. View

10.

Trynka G, Zhernakova A, Romanos J, Franke L, Hunt K, Turner G . Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut. 2009; 58(8):1078-83. DOI: 10.1136/gut.2008.169052. View

11.

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

12.

Nair R, Callis Duffin K, Helms C, Ding J, Stuart P, Goldgar D . Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009; 41(2):199-204. PMC: 2745122. DOI: 10.1038/ng.311. View

13.

Capon F, Burden A, Trembath R, Barker J . Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol. 2011; 132(3 Pt 2):915-22. PMC: 3378482. DOI: 10.1038/jid.2011.395. View

14.

Ellis C, Gorsulowsky D, Hamilton T, Billings J, Brown M, HEADINGTON J . Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986; 256(22):3110-6. View

15.

. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet. 2009; 41(7):824-8. DOI: 10.1038/ng.396. View

16.

Ortega C, Fernandez-A S, Carrillo J, Romero P, Molina I, Moreno J . IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009; 86(2):435-43. DOI: 10.1189/JLB.0109046. View

17.

Ciric B, El-Behi M, Cabrera R, Zhang G, Rostami A . IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol. 2009; 182(9):5296-305. DOI: 10.4049/jimmunol.0900036. View

18.

Austin L, Ozawa M, Kikuchi T, Walters I, Krueger J . The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1.... J Invest Dermatol. 1999; 113(5):752-9. DOI: 10.1046/j.1523-1747.1999.00749.x. View

19.

Chang S, Dong C . A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007; 17(5):435-40. DOI: 10.1038/cr.2007.35. View

20.

Ghoreschi K, Weigert C, Rocken M . Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol. 2007; 25(6):574-80. DOI: 10.1016/j.clindermatol.2007.08.012. View